BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $51.67 Consensus Price Target from Brokerages
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year target price […]
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year target price […]
